Cargando…

Successful dabigatran reversal after subdural hemorrhage using idarucizumab in a mobile stroke unit: A case report

RATIONALE: Idarucizumab is a specific reversal agent for patients with bleeding related to the anticoagulant dabigatran. There are no prior descriptions of Idarucizumab administration in the prehospital setting for intracranial hemorrhage. PATIENT CONCERNS: An 82-year-old woman treated with dabigatr...

Descripción completa

Detalles Bibliográficos
Autores principales: Thirunavukkarasu, Sibi, Kalashyan, Hayrapet, Jickling, Glen, Jeerakathil, Thomas Joseph, Jayaprakash, Harsha Kamble, Buck, Brian H., Shuaib, Ashfaq, Butcher, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249931/
https://www.ncbi.nlm.nih.gov/pubmed/32481289
http://dx.doi.org/10.1097/MD.0000000000020200
Descripción
Sumario:RATIONALE: Idarucizumab is a specific reversal agent for patients with bleeding related to the anticoagulant dabigatran. There are no prior descriptions of Idarucizumab administration in the prehospital setting for intracranial hemorrhage. PATIENT CONCERNS: An 82-year-old woman treated with dabigatran for atrial fibrillation developed acute focal weakness. This led to activation of emergency medical services and assessment in the mobile stroke unit (MSU). DIAGNOSIS: Computed tomography of the brain performed in the MSU revealed an acute subdural hematoma. INTERVENTIONS: The patient was treated with Idarucizumab in the MSU. OUTCOMES: The subdural hematoma was treated with a burr hole evacuation and the patient was discharged to a rehabilitation facility without residual focal neurological deficits. LESSONS: Idarucizumab can be used safely and effectively to treat dabigatran-associated intracranial hemorrhage in the prehospital setting.